Checkpoint Therapeutics, Inc. clinical trials
Acquired by Sun Pharmaceutical Industries Limited, May 30, 2025 · source ↗
The registry lists 3 studies whose lead sponsor is Checkpoint Therapeutics, Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Apr 2, 2025.
Before and after it joined Sun Pharmaceutical Industries Limited
- First submitted before Checkpoint Therapeutics, Inc. became part of Sun Pharmaceutical Industries Limited
- 3
- First submitted after Checkpoint Therapeutics, Inc. became part of Sun Pharmaceutical Industries Limited
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Checkpoint Therapeutics, Inc.3 studies
Something wrong with this grouping? Tell us on the Sun Pharmaceutical Industries Limited page.
Studies
Recruiting first, then most recently updated. Showing 3 of 3. All Sun Pharmaceutical Industries Limited studies →
- Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLCTerminatedNCT04786964Phase 3
Sponsor listed in the registry: Checkpoint Therapeutics, Inc. · First submitted before Checkpoint Therapeutics, Inc. became part of Sun Pharmaceutical Industries Limited
- Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced CancersActive, not recruitingNCT03212404Phase 1
Sponsor listed in the registry: Checkpoint Therapeutics, Inc. · First submitted before Checkpoint Therapeutics, Inc. became part of Sun Pharmaceutical Industries Limited
- Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid TumorsCompletedNCT02926768Phase 1
Sponsor listed in the registry: Checkpoint Therapeutics, Inc. · First submitted before Checkpoint Therapeutics, Inc. became part of Sun Pharmaceutical Industries Limited